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Abstract
Cerebrospinal fluid (CSF) total prion protein (t-PrP) is decreased in sporadic Creutzfeldt-Jakob disease (sCJD). However, data on
the comparative signatures of t-PrP across the spectrum of prion diseases, longitudinal changes during disease progression, and
levels in pre-clinical cases are scarce. T-PrP was quantified in neurological diseases (ND, n = 147) and in prion diseases from
different aetiologies including sporadic (sCJD, n = 193), iatrogenic (iCJD, n = 12) and genetic (n = 209) forms. T-PrP was also
measured in serial lumbar punctures obtained from sCJD cases at different symptomatic disease stages, and in asymptomatic
prion protein gene (PRNP) mutation carriers. Compared to ND, t-PrP concentrations were significantly decreased in sCJD, iCJD
and in genetic prion diseases associated with the three most commonmutations E200K, V210I (associated with genetic CJD) and
D178N-129M (associated with fatal familial insomnia). In contrast, t-PrP concentrations in P102L mutants (associated with the
Gerstmann-Sträussler-Scheinker syndrome) remained unaltered. In serial lumbar punctures obtained at different disease stages of
sCJD patients, t-PrP concentrations inversely correlated with disease progression. Decreased mean t-PrP values were detected in
asymptomatic D178-129M mutant carriers, but not in E200K and P102L carriers. The presence of low CSF t-PrP is common to
all types of prion diseases regardless of their aetiology albeit with mutation-specific exceptions in a minority of genetic cases. In
some genetic prion disease, decreased levels are already detected at pre-clinical stages and diminish in parallel with disease
progression. Our data indicate that CSF t-PrP concentrations may have a role as a pre-clinical or early symptomatic diagnostic
biomarker in prion diseases as well as in the evaluation of therapeutic interventions.
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Introduction
Transmissible spongiform encephalopathies are fatal neurode-
generative disorders characterised by rapid progression and
microvacuolation in the grey matter of the brain. They are also
known as prion diseases relating to the causative agent, which is
the abnormally folded isoform the prion protein scrapie (PrPsc)
that creates insoluble aggregates and accumulate in the brain [1].
Prion diseases affecting humans include sporadic Creutzfeldt-
Jakob disease (sCJD), genetic prion diseases (gPD) and acquired
forms, such as iatrogenic CJD (iCJD) or variant CJD (vCJD).
sCJD is themost prevalent form accounting for about 85–90%of
total cases, followed by hereditary forms (~ 10%). By contrast,
acquired forms only account for at most 2–5% of prion disease
cases [2, 3]. Despite sharing a common pathological agent, prion
diseases present a broad heterogeneity in clinical symptoms and
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disease manifestations. A cause of variability is the polymor-
phism at codon 129 of the PrP encoding gene, PRNP, which
can be methionine (M129) or valine (V129) [4]. In combination
with biochemically characterised conformational variants of
PrPsc, sCJD can be stratified into at least six molecular subtypes,
with MM1/MV1 and VV2 the most prevalent ones (> 80% of
total sCJD cases [5]). gPD are associated with specific mutations
in the PRNP and include familial/genetic Creutzfeldt-Jakob dis-
ease (gCJD), Gerstmann-Sträussler-Scheinker syndrome (GSS-
S) and familial fatal insomnia (FFI). Several PRNP mutations
cause gCJD and GSS-S (reviewed elsewhere [6]), with E200K
and V210I the most prevalent mutations in gCJD and P102L in
GSS-S. In contrast, FFI is associated with a unique haplotype,
D178N-129M (D178N-M) [6, 7]. Acquired human prion dis-
eases develop from exogenous prions and are transmitted from
infected humans (iCJD) or cattle (vCJD). iCJD is caused by
human-to-human transmission during medical treatments, with
dura matter grafts and administration of human growth hormone
the main causes of cross-contamination through surgical and
medical procedures [8].
Clinical diagnosis of prion diseases is supported by cere-
brospinal fluid (CSF) biomarkers. The CSF profile of prion
disease patients is characterised by elevated concentrations of
surrogate protein markers of the pathology such as 14-3-3, tau
and alpha-synuclein [9–11], as well as by the presence of
prion seeding activity [12]. By contrast, the CSF total PrP (t-
PrP) concentrations are decreased in sCJD. The specificity of
this decrease remains unclear as some authors reported re-
duced CSF t-PrP in various neurodegenerative diseases, such
as Alzheimer’s disease (AD), dementia with Lewy bodies and
Parkinson’s disease [13], while others suggested that t-PrP is
specifically reduced in sCJD compared to AD, supporting its
use in the differential diagnostic context [14, 15]. Among
sCJD molecular subtypes, no difference was found in
CSF t-PrP levels between MM1 and VV2 cases [16] and
scant data exist for acquired cases. When CSF t-PrP was
investigated by western blot, no variation appeared in the
truncation or glycosylation state of the protein between
different sCJD subtypes or in comparison with hereditary
prion diseases [17–19]. To date, no further quantification
of CSF t-PrP has been carried out in genetic prion dis-
eases, including a significant number of mutation types.
In addition, few data are available about the relationship of
CSF t-PrP with demographic parameters, as are data on
longitudinal t-PrP CSF levels in prion diseases. A prelim-
inary exploration showed a decrease in t-PrP levels with
disease progression although quantification was lacking
and only six sCJD cases were studied [18].
While age does not influence t-PrP concentration in dis-
eased individuals, low levels are associated with advanced
disease stages [13]. Correlation analysis with other CSF bio-
markers indicated a direct correlation between t-PrP and
amyloid-beta 42 peptide in sCJD [13].
The goal of the present study was to provide complete CSF t-
PrP signatures across the broad spectrum of prion diseases. Thus,
we quantified theCSF t-PrP in a large number of cases that include
sCJD, iCJD, various forms of gPD, and diverse neurological dis-
eases composing our control group. In addition, we also investi-
gated longitudinal CSF t-PrP alterations in serial lumbar punctures
from sCJD cases and asymptomatic PRNP mutant carriers.
Methods
Patients
The study included 561 CSF samples. Samples from patients
with non-primarily neurodegenerative neurological diseases
(ND, n = 147) and sporadic Creutzfeldt-Jakob disease (sCJD,
n = 193) were collected at the Clinical Dementia Center and the
National Reference Center for CJD Surveillance at the
University Medical Center of Göttingen (Germany). The ND
group was composed of cases diagnosed with neurological con-
ditions not associated with neurodegenerative pathology includ-
ing the following diagnostic groups: psychosis, paranoid psycho-
sis, bipolar disorder, schizophrenia, ischemic stroke, multiple ce-
rebral infarcts, epilepsy, meningitis, alcohol abuse, vertigo, acute
or chronic headache, pain syndromes, acute hypoxia,
polyneuropathy, cerebral lymphoma, astrocytoma and
paraneoplasia. ND cases were diagnosed according to acknowl-
edged standard neurologic clinical and para-clinical findings
based on the ICD 10 definitions. The presence of neurodegener-
ative diseases in the ND group was excluded by follow-up eval-
uations. All patients with sCJD were classified as probable or
definite cases according to diagnostic consensus criteria [20, 21].
Iatrogenic (n = 12) and genetic (n= 209) prion diseases were
collected in the following CJD reference centres: (1) Clinical
Dementia Center and the National Reference Center for CJD
Surveillance at the University Medical Center, Göttingen,
Germany, (2) Neurochemistry Laboratory, Neurology
Department of Coimbra University Hospital, Coimbra,
Portugal, (3) Alzheimer’s Disease and Other Cognitive
Disorders Unit, Hospital Clínic, Barcelona, Spain, (4) National
Centre of Microbiology-Carlos III Institute of Health, Madrid,
Spain, (5) Istituto Superiore di Sanità, Rome, Italy, (6) Slovak
Medical University, Bratislava, Slovakia, (7) Australian National
CJD Registry, The Florey Department of Neuroscience and
Mental Health, Melbourne, Australia, and (8) Department of
Neurology, Memory and Aging Center, University of
California, San Francisco (UCSF), USA. The diagnoses of ge-
netic prion diseases were carried out according to surveillance
criteria after prion protein gene (PRNP) analysis [22] and World
Health Organization (WHO) criteria [23]. Iatrogenic CJD was
diagnosed according to established WHO criteria [23]. Eleven
iatrogenic cases were associated with dura matter grafts and one
with corneal transplantation.
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CSF Tests
CSF t-PrP was centrally quantified (Clinical Dementia Center-
Göttingen) using a commercially available enzyme-linked im-
munosorbent assay (ELISA) specific for human prion protein
(Analytik Jena AG). Inter- and intra-assay coefficients of var-
iation in our study were below 18 and 12%, respectively. CSF
neurofilament-light (NFL) was quantified using a commer-
cially available ELISA (Uman-Diagnostics). The analysts
were masked to clinical data.
Table 1 Demographic and
biomarkers data from our study
population. Number of cases (n),
age in years (mean values ±
standard deviation), sex (female
(f)/males (m)), codon 129 PRNP
genotype and t-PrP
concentrations (mean values
(mean) ± standard deviation (SD)
in ng/mL), and 95% CI (in ng/
mL) are indicated.Mutation in the
PRNP gene is indicated for
genetic prion diseases (gPD).
gCJD genetic Creutzfeldt-Jakob
disease, GSS-S Gerstmann-
Sträussler-Scheinker syndrome,
FFI fatal familial insomnia,M
methionine, V valine, NA not
available. Other mutations/
variants refer to cases diagnosed
as prion disease with changes on
the PRNP gene without clear
evidence of being disease
causative mutations
Number
of cases
Age Sex PRNP 129 t-PrP
Mean ± SD
(years)
f/m MM MV VV NA Mean ± SD
(ng/mL)
95% CI
(ng/mL)
Control
ND 147 65 ± 11 78/69 0 0 0 147 230 ± 140 207–253
Sporadic prion disease
sCJD 193 65 ± 10 114/79 74 37 45 37 120 ± 83 108–132
Aquired prion disease
iCJD 12 48 ± 10 5/7 9 2 0 1 95 ± 71 50–140
Genetic prion disease
Pathogenic variants associated to gCJD
D178N-V 1 48 1/0 0 0 1 0 29 0
V180l 1 77 0/1 1 0 0 0 300 0
T188A 1 82 1/0 1 0 0 0 142 0
T188K 1 57 1/0 0 1 0 0 173 0
K194E 1 71 0/1 0 1 0 0 232 0
E196K 3 69 ± 4 2/1 1 1 1 0 69 ± 4 59–79
E200K 66 61 ± 11 39/27 45 18 2 1 98 ± 77 78–117
R208H 4 62 ± 7 2/2 3 1 0 0 243 ± 146 10–475
V210l 41 64 ± 10 24/17 31 8 2 0 161 ± 147 114–207
P238S 1 68 1/0 0 1 0 0 52 0
Pathogenic variants associated to GSS-S
P102L 13 53 ± 11 8/4* 11 1 1 0 200 ± 148 111–289
P105T 3 36 ± 17 2/1 0 3 0 0 225 ± 168 0–642
G114V 1 20 0/1 0 1 0 0 114 0
A117V 1 47 1/0 0 0 1 0 95 0
A133V 1 62 1/0 1 0 0 0 68 0
V176G 1 61 1/0 0 0 1 0 31 0
F198S 1 51 0/1 0 1 0 0 47 0
Q217R 1 59 0/1 1 0 0 0 165 0
Y218N 1 NA 1/0 0 1 0 0 254 0
Pathogenic variants associated to FFI
D178N-M 47 50 ± 10 16/31 31 16 0 0 119 ± 94 91–146
Insert mutations
OPRI 14 63 ± 9 8/6 5 4 5 0 105 ± 113 40–171
Nonsense mutations
Q160X 1 27 0/1 1 0 0 0 30 0
Other mutations/variants
Q52P 1 80 1/0 0 1 0 0 141 0
N173K 1 73 0/1 0 1 0 0 203 0
Q212H 1 63 1/0 1 0 0 0 37 0
l215V 1 77 0/1 1 0 0 0 81 0
*Sex unknown in one case
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Genetic Tests
For detection of a prion disease-associated mutation and as-
sessment of codon 129 polymorphism in PRNP, genetic test-
ing was performed as described before [24].
Statistical Analysis
For two group comparisons of biomarker levels, non-
parametric Mann-Whitney U tests were used. For compari-
sons between multiple groups, Kruskal-Wallis tests followed
by Dunn’s post hoc tests were applied. To assess the diagnostic
accuracy of t-PrP, receiver operating characteristic (ROC) curve
analyses were carried out and areas under the curve (AUC)with
95% confidence intervals (95% CI) were calculated. Spearman
rank correlation coefficients were used to assess associations
between continuous biomarker levels. Bootstrap one-tail tests
for paired ROC curves based on the pROC-R package with
boot replicates = 10,000 were used to assess differences in the
diagnostic accuracy between biomarkers [25]. Longitudinal
biomarker data were assessed using a multi-level mixed linear
model. For the analysis of differences on t-PrP concentrations
Fig. 1 Analysis of CSF t-PrP concentrations in sporadic, iatrogenic and
genetic prion diseases. a Whisker and boxplots of CSF t-PrP
concentrations in non-primarily neurodegenerative neurological
diseases (ND), sporadic Creutzfeldt-Jakob disease (sCJD), iatrogenic
Creutzfeldt-Jakob disease (iCJD) and genetic prion diseases (gPD)
associated with mutations in the PRNP gene E200K, V210I, D178N-M
and P102L. Boxes indicate 25th to 75th percentiles and whiskers
minimum to maximum values. Statistical significance was set at *p <
0.05, **p < 0.01, ***p < 0.001. b Receiver operating characteristic
curves for sCJD, iCJD and gPDs associated with mutations E200K,
V210I, D178N-M and P102L versus the ND group are shown. Area
under the curve (AUC) and 95% confidence interval (CI) are shown for
t-PrP analysis
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between different cohorts, only cohorts including enough cases
to perform normality tests were used.
Data Availability The datasets used and/or analysed during the
current study are available from the corresponding author on
reasonable request.
Results
CSF t-PrP in Prion Disease of Different Aetiologies
CSF t-PrP concentrations were assessed in ND, sCJD, iCJD
and gPD cases (Table 1). Compared to ND, mean t-PrP levels
were lower in all types of prion diseases, with the exception of
gPD associated with V180I, K194E and Y218N mutations
(one case of each was available), and the R208H mutation
(four cases available). Other mutations and variants also
displayed similar concentrations to those reported in ND
(P102L, P105L and N173K).
In order to assess if there were differences in t-PrP levels
among diagnostic groups, t-PrP concentrations in ND, sCJD,
iCJD and the four most prevalent forms of genetic prion diseases
(E200K, V210I, D178N-M and P120L mutations) were further
analysed in a multiple comparison test. Compared to ND, t-PrP
was lower in sCJD (p< 0.001), iCJD (p< 0.01) and in gPD as-
sociated with E200K (p< 0.001), V210I (p< 0.01) and D178N-
Mmutations (p< 0.001), but not in P102L cases (Fig. 1a). Lowest
t-PrP concentrations were found in iCJD (95 ± 71 ng/mL) and
E200K (98 ± 77 ng/mL) (Table 1), but no statistical differences
among different forms of prion diseases were detected.
AUCs for the discrimination of sCJD, iCJD and gPD
E200K, V210I and D178N-M from ND ranged from 0.69 to
0.83, indicating moderate potential for a diagnostic test (Fig.
1b). In contrast, t-PrP levels showed no diagnostic value in
distinguishing P102L from ND (AUC = 0.57, p = 0.40)
(Fig. 1b).
CSF from gPD cases was obtained from different countries
(see “Methods”). No differences were found when comparing
t-PrP concentrations from different cohorts for the E200K,
D178N-M and V210 mutations (Suppl. Fig. 1).
Established CSF prion disease biomarkers such as 14-3-
3, tau [26, 27] and RT-QuIC [28] show a high diagnostic
accuracy in the discrimination of non-prion disease cases
from sCJD and gCJD E200K and V210I. However, they
present limited value in the diagnosis of genetic prion dis-
ease associated with D178N-M. We recently reported ele-
vated CSF NFL in D178N-M cases and showed moderate
diagnostic potential for t-PrP in this analysis; therefore, we
explored the ability of NFL/t-PrP ratio for improving the
discrimination of D178N-M from ND. The AUC value in
D178N-M cases using the NFL/t-PrP ratio (AUC = 0.97,
95% CI 0.95–0.99) was superior to that obtained by t-PrP
only (AUC = 0.78, 95% CI 0.70–0.86, p < 0.001), but not
relatively increased when compared to NFL alone (AUC =
0.96, 95% CI 0.93–0.98, p = 0.2).
The presence of octapeptide repeat insertions (OPRI)
in the N-terminal region of the PRNP gene is linked with
genetic prion diseases. High clinical and neuropatholog-
ical heterogeneity in ORPI carriers is associated to the
number of insert mutations (one to nine) [29–31] with
the likelihood that low OPRI numbers are not pathogenic
[32]. Mean t-PrP levels in cases with OPRI mutations
were lower than in ND cases (p = 0.003) (Table 1).
However, no association between CSF t-PrP levels and
number of inserts was detected in our study population
(p = 0.38) (Fig. 2).
Associations of Demographic and Genetic Parameters
with t-PrP Concentrations
In prion diseases, CSF t-PrP levels were associated neither with
age at onset (p = 0.10) (Fig. 3a) nor with sex (p= 0.21) (Fig. 3b).
Lack of associationwith age and sexwas also detected in theND
group (data not shown). CSF t-PrP concentrations were not sta-
tistically different between prion disease cases harbouring
methionine/methionine [MM] (129 ± 107 ng/mL, n = 219),
methionine/valine [MV] (114 ± 88 ng/mL, n = 99) and valine/
valine [VV] (112 ± 85 ng/mL, n = 59) at codon 129 of the
PRNP gene (p= 0.58) (Fig. 2c). Similarly, no differences were
detected between different sCJDmolecular subtypes in the subset
of cases with neuropathological prion disease confirmation and
available prion type (MM1/MV1 110 ± 80 pg/mL, n= 55; MV2
84 ± 61 pg/mL, n = 6; VV2 88 ± 77, n= 16) (p= 0.16) (Fig. 3d).
To investigate whether t-PrP concentrations are associated with
different pathological phenotypes among a mutation type,
D178N-M and E200K cases were stratified according to their
codon 129 PRNP genotype, which influences their clinico-
Fig. 2 Influence of the number of octapeptide repeat insertions (OPRI) in
the prion protein gene (PRNP) on CSF t-PrP concentrations. Association
analysis between t-PrP concentrations and number of OPRI in the PRNP
gene. Spearman rank correlation coefficients were used
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pathological features [33, 34]. t-PrP levels were neither different
between D178-MM and -MV cases (Fig. 3e) nor between
E200K-MM and -MV cases (Fig. 3f).
CSF t-PrP along Disease Stages
t-PrP levels were quantified in sequentially repeated lum-
bar punctures (LPs) obtained from 20 sCJD cases (2 LPs
available in 19 cases and 3 LPs available in 1 case). To
normalise time intervals between LPs, samples were
grouped into three categories according to whether they
underwent LP in the first (time of LP to disease onset/
total duration of the disease < 0.33), second (0.33–0.66)
or third (> 0.66) stage of the disease, as previously report-
ed [35, 36]. In 15 LPs, t-PrP concentrations were lower in
the follow-up LP compared to the initial estimate, while
in 5 LPs, t-PrP concentrations were higher at advanced
disease stages (Fig. 4). Using a multi-level mixed linear
model, a decrease in t-PrP of 24.5 per unit in disease
stages was calculated (95% CI 12.8–48.8, p = 0.005).
Fig. 3 Influence of demographic and PRNP codon 129 genetic factors on
CSF t-PrP concentrations in prion diseases. a Association analysis
between t-PrP concentrations and age at disease onset (in years) in all
prion disease cases (sCJD, iCJD and gPD). Spearman rank correlation
coefficients were used. b t-PrP in prion diseases stratified by sex. c t-PrP
concentrations in prion diseases stratified by prion protein gene (PRNP)
codon 129 polymorphism (M methionine, V valine) in probable and
definite prion disease cases. d t-PrP concentrations in definite sCJD
cases stratified by sCJD molecular subtypes. e t-PrP concentrations in
D178-MM and MV cases. f t-PrP concentrations in E200K-MM and
MV cases. Kruskal-Wallis test followed by Dunn’s post hoc tests
(correction for multiple testing) was applied for multiple comparisons
and Mann-Whitney U test for two group comparisons
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CSF in Pre-Clinical PRNP Mutation Carriers
t-PrP concentrations were analysed in a subset of asymptom-
atic PRNP mutation carriers from the UCSF cohort and were
descriptively compared with symptomatic cases from the
same cohort (symptomatic, UCSF), with the whole population
of cases included in the present study (symptomatic, ALL)
and with the ND cases (Suppl. Fig. 2). For some cases, serial
LPs from the mutation carriers were available.
In E200K, pre-symptomatic carriers (17 LPs from 14
cases) displayed t-PrP concentrations similar to ND controls
(Suppl. Fig. 2) and higher than those detected in symptomatic
cases in the UCSF cohort (1 case) and in the whole cohort of
E200K patients (Fig. 5a). In D178N-M cases, pre-
symptomatic carriers showed similar levels like symptomatic
D178N-M patients from the UCSF and the whole D178N-M
cohort, although only six LPs from three individuals were
available (Fig. 5b), limiting any meaningful conclusions. In
P102L carriers, t-PrP concentrations were similar between
pre-symptomatic (two cases available) and symptomatic pa-
tients, in agreement with the absence of alterations between
ND and symptomatic cases described above (Fig. 5c).
Discussion
In this study, we report the comparative signatures of CSF t-
PrP concentrations across the spectrum of prion diseases.
While decreased t-PrP concentrations are well-reported in
sCJD cases [13–16, 18], data on genetic and iatrogenic cases
have hitherto been quite limited and in most of the cases,
restricted to single case reports. Our study validates previous
observations of decreased CSF t-PrP in sCJD cases compared
to controls and other non-neurodegenerative neurological
conditions evaluated by ELISA [13–16, ] and by immunoblot-
ting techniques [18]. Additionally, although the total number
of samples was relatively low, our data clearly point to the
presence of reduced t-PrP concentrations in iCJD.
Low t-PrP concentrations were observed in genetic prion
diseases associated with mutations E200K, D178N-M and
V210I, but not in P102L cases supporting that among gCJD
and GSS-S-associated mutations, t-PrP levels were not homo-
geneous. Genetic CJD patients with V180I, K194E and
R208H mutations showed normal t-PrP concentrations, while
as did GSS-S patients with P102L, P105L and Y218N muta-
tions. The rest of the mutations displayed decreased or inter-
mediate t-PrP levels. In this regard, well-known disease caus-
ing mutations such as A117V, P102L, E200K and D178N-M
[37] showed diverse t-PrP concentrations, while some muta-
tions with no strong evidence of increased risk for developing
the disease (e.g. A133V, V176G, I215V, P238S) displayed
reduced t-PrP levels. Although these results should be
interpreted with caution due to the low number of cases (sta-
tistical analysis was carried out for the most prevalent forms
only), our data suggest the presence of highly heterogeneous
profiles, which are not associated with disease phenotype.
Indeed, D178N-M cases, displaying a specific clinico-
pathological phenotype compared to sCJD, iCJD and gCJD
E200K and V210I, presented low t-PrP concentrations.
Additionally, no differences on t-PrP levels were detected be-
tween D178N-MM and -MV cases, although both groups
show distinct clinical features and neuropathological profiles
[33, 38].Moreover, similar t-PrP levels were detected between
E200K-MM and -MV cases, despite the presence of different
types of PrP depositions in the brain tissue, with a synaptic
pattern for MM subjects and granules and plaque-like struc-
tures for MV subjects [34].
Overall, the analysis of CSF signatures demonstrated high
variation in t-PrP concentrations across the diagnostic groups.
This, together with a moderate diagnostic accuracy in discrimi-
nating prion disease cases from ND controls (AUC of 0.76 for
sCJD), argues against the use of t-PrP quantification alone as a
diagnostic biomarker for prion diseases in clinical practice.
However, the tentative decrease of t-PrP concentrations along
disease duration observed in serial lumbar punctures from the
same patients indicates that, for a given case, longitudinal alter-
ations on t-PrP levels may have a potential role in the evaluation
of disease progression, as well as in the evaluation of the efficacy
of a potential therapeutic intervention. In this regard, other CSF
prion biomarkers such as tau, alpha-synuclein and NFL have
been able to predict disease duration [36, 39, 40], but show stable
concentrations along disease progression [35, 36, 40]. These
markers reflect pathological alterations associated with the neu-
rodegeneration process such as neuro-axonal degeneration and
white matter involvement. In contrast, decreased t-PrP levels
may reflect primary alterations in the molecular process
Fig. 4 Association between CSF t-PrP levels and disease duration in
sCJD patients. t-PrP concentrations in serial lumbar punctures (LPs) in
sCJD cases at different stages of the disease. Samples were grouped in
three categories according to whether they underwent LP in the first (<
0.33), second (0.33–0.66) or third (> 0.66) stage of an individual’s disease
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associated with the formation of prions. Broadly similar to amy-
loid-beta42 levels in AD, the decrease of CSF t-PrP concentra-
tions in prion cases is speculated to be a consequence of the
misfolding of the cellular prion protein (PrPc) into PrPsc with
consequent “trapping” of the protein in aggregates, limiting the
amount of soluble PrP filtering to the CSF. Based on this hypoth-
esis, it could be assumed that CSF t-PrP levels would be highly
dependent on prion disease aetiology and sCJD subtypes, which
differ with respect to the neuropathological profiles and type of
PrPsc aggregates [16, 21, 34]. For instance, in D178N-M cases,
CSF t-PrP concentrations are decreased despite the reduced
levels of PrPsc in the brain parenchyma, which is usually only
detectable in the entorhinal cortex and in some cases with CJD-
type alterations in the deep regions of the temporal cortex.
Therefore, the absence of differences in CSF t-PrP concentrations
between prion diseases displaying different types of PrP brain
aggregates indicates that additional factors appear to explain the
singular signatures of CSF t-PrP across the spectrum of prion
diseases. Interestingly, decreased PrP expression was found in
the two most prevalent sCJD subtypes (MM1 and VV2) [16],
Fig. 5 CSF t-PrP concentrations
in asymptomatic genetic prion
diseases. CSF t-PrP
concentrations and age of LP in
pre-symptomatic PRNP mutation
carries for the E200K (a),
D178N-M (b) and P102L (c)
mutations from the UCSF cohort.
Black spots indicate a LP. Black
spots connected with a black line
indicating serial LPs from the
same patient. Red lines indicate
mean t-PrP concentrations for
symptomatic cases from all the
cases analysed in the present
study (symptomatic, ALL).
Dashed red lines indicate mean t-
PrP concentrations for
symptomatic cases from the
UCSF cohort (symptomatic,
UCSF). Mean age at onset from
UCSF cohort and from all cases
are indicated with a blue arrow
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as well as in the thalamus and entorhinal cortex of D178N-M
cases [41] causing a reduction of PrP levels in the brain, and
potentially in the CSF. Moreover, the decrease in CSF t-PrP
could be associated with a decrease in proteinase-sensitive inter-
mediate PrP isoforms not detected by the ELISA t-PrP assay.
In pre-symptomatic carriers of the D178N-M mutation, t-PrP
concentrations were similar to those detected in symptomatic
cases and lower than those in ND. This indicates that, at least
in D178N-M, t-PrP could be a potential pre-clinical biomarker of
the pathology. In contrast, pre-symptomatic E200K carriers
harboured t-PrP higher than in clinical cases and similar to values
measured in NDs. Although the low number of cases available
impedes a statistical evaluation and, therefore, results remain
descriptive, several aspects should be underlined. First, the pres-
ence of reduced t-PrP concentrations is not a general observation
for all mutations. Whether these results are associated with
mutation-specific disease duration, low number of cases, data
dispersion and/or confounders such as heterogeneity of age at
onset needs to be further explored in larger cohorts. Therefore,
we cannot exclude t-PrP as a potential pre-clinical biomarker for
other mutation types or prion disease types. Second, despite the
absence of studies addressing the quantification of t-PrP levels in
pre-symptomatic cases, we recently detected lower t-PrP concen-
trations in the CSF of pre-clinical and clinical naturally occurring
scrapie [42], which would support the idea that reduced t-PrP
concentrationsmay happen at pre-clinical and early prion disease
stages.
Conclusions
Herein, we report the largest and most complete study of the
levels of CSF t-PrP across the spectrum of prion diseases,
including multiple cases of gPD associated with a broad range
of PRNP mutations. We have confirmed previous data dem-
onstrating reduced CSF t-PrP in sCJD.
Although the diagnostic potential of CSF t-PrP alone is
perhaps limited, its combination with other biomarkers may
heighten its utility. Importantly, the observed CSF t-PrP de-
cline along disease progression in sCJD and in pre-
symptomatic carriers of certain mutations such as D178N-M
cases deserves further investigation towards potential transla-
tional application in clinical practice.
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